CA3242074A1 - 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors - Google Patents
1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitorsInfo
- Publication number
- CA3242074A1 CA3242074A1 CA3242074A CA3242074A CA3242074A1 CA 3242074 A1 CA3242074 A1 CA 3242074A1 CA 3242074 A CA3242074 A CA 3242074A CA 3242074 A CA3242074 A CA 3242074A CA 3242074 A1 CA3242074 A1 CA 3242074A1
- Authority
- CA
- Canada
- Prior art keywords
- oxazepine
- pyrido
- bcl
- pyrrolo
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 | |
| US63/267,018 | 2022-01-21 | ||
| PCT/US2023/060944 WO2023141536A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242074A1 true CA3242074A1 (en) | 2023-07-27 |
Family
ID=85382827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242074A Pending CA3242074A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4466273A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7714811B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240136972A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119053610A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128310A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023210279A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242074A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024009334A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312709A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008840A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340210A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023141536A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202340210A (zh) * | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002032A (es) | 2017-08-23 | 2020-09-17 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de bcl-2. |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| MX2022010410A (es) | 2020-02-24 | 2022-12-07 | Guangzhou Lupeng Pharmaceutical Company Ltd | Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. |
| TW202340210A (zh) * | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 |
-
2023
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023210279A1 (en) | 2024-05-23 |
| JP2025504382A (ja) | 2025-02-12 |
| IL312709A (en) | 2024-07-01 |
| AR128310A1 (es) | 2024-04-17 |
| CO2024009334A2 (es) | 2024-07-18 |
| TW202340210A (zh) | 2023-10-16 |
| US20230234971A1 (en) | 2023-07-27 |
| KR20240136972A (ko) | 2024-09-19 |
| US20250066388A1 (en) | 2025-02-27 |
| MX2024008840A (es) | 2024-07-25 |
| EP4466273A1 (en) | 2024-11-27 |
| JP7714811B2 (ja) | 2025-07-29 |
| WO2023141536A1 (en) | 2023-07-27 |
| US11964990B2 (en) | 2024-04-23 |
| US20260028356A1 (en) | 2026-01-29 |
| CN119053610A (zh) | 2024-11-29 |
| JP2025160251A (ja) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2295402A3 (en) | Antibacterial agents | |
| PH12021500017A1 (en) | Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| EP1467970A4 (en) | HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE | |
| MX2025010928A (es) | Compuestos de alquinil quinazolina | |
| UA84878C2 (ru) | Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения | |
| IL158667A0 (en) | Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections | |
| DK1159279T3 (da) | 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler | |
| NZ536750A (en) | 7-Aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | |
| WO2002090332A3 (en) | Novel aeylheteroalkylaminε derivatives | |
| MX2007006497A (es) | Nuevos derivados de pirrolo [3,2-d] pirimidin-4-ona y su uso en terapia. | |
| MX2024009177A (es) | Compuestos y metodos de uso | |
| MA27566A1 (fr) | Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4 | |
| MX2009005982A (es) | Derivados de quinolina antibacterianos. | |
| MX2024008840A (es) | Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina. | |
| WO2023141432A3 (en) | Apol1 inhibitors and methods of use | |
| SE0301320D0 (sv) | Positive modulators of nicotinic acetylcholine receptors | |
| ZA202309204B (en) | Lactivicin compounds, their preparation and use as antibacterial agents | |
| SE0302756D0 (sv) | Novel Compounds | |
| MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
| MXPA05009688A (es) | Derivados de naftiridina como agentes antibacterianos. | |
| AU2003218130A1 (en) | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors | |
| MX2024005063A (es) | Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos. | |
| CA2380455A1 (en) | 9a-azalides with antibacterial activity | |
| WO2002072581A3 (en) | Pyrazolopyriadine derivatives | |
| AU2006299042A8 (en) | HIV integrase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |